XMEN disease: A new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus

Blood

Volumn 123, Issue 14, 2014, Pages 2148-2152

  Li, Feng Yen ^a,b   Chaigne Delalande, Benjamin ^a   Su, Helen ^c   Uzel, Gulbu ^a   Matthews, Helen ^a   Lenardo, Michael J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Laboratory of Host Defenses   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MAGNESIUM; MAGNESIUM ION; MESSENGER RNA; RITUXIMAB; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN;

B LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; LOSS OF FUNCTION MUTATION; LYMPHOPROLIFERATIVE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; X CHROMOSOME INACTIVATION; XMEN DISEASE;

ADULT; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY, INNATE; MAGNESIUM; MAGNESIUM DEFICIENCY; NEOPLASMS; SYNDROME; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84899050112     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-538686     Document Type: Review

References (16)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481-492. (Pubitemid 30646489)
2. Balfour HH Jr, Odumade OA, Schmeling DO, et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013;207(1):80-88.
3. Parvaneh N, Filipovich AH, Borkhardt A. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br J Haematol. 2013;162(5):573-586.
4. Li FY, Chaigne-Delalande B, Kanellopoulou C, et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature. 2011;475(7357):471-476.
5. Chaigne-Delalande B, Li FY, O'Connor GM, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013;341(6142):186-191.
6. Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835-5849.
7. Zhou H, Clapham DE. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. Proc Natl Acad Sci USA. 2009;106(37):15750-15755.
8. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011;127(6):1329-1341.
9. Pappworth IY, Wang EC, Rowe M. The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol. 2007;81(2):474-482. (Pubitemid 46067874)
10. Nakajima H, Cella M, Bouchon A, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol. 2000;30(11):3309-3318.
11. Palendira U, Low C, Chan A, et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 2011;9(11):e1001187.
12. Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med. 2000;192(3):337-346. (Pubitemid 30629159)
13. Sharifi R, Sinclair JC, Gilmour KC, et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood. 2004;103(10):3821-3827. (Pubitemid 38596301)
14. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood. 2009;114(13):2657-2666.
15. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734-738. (Pubitemid 35177960)
16. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6(10):2418-2428. (Pubitemid 44359429)